Ford Motor (F) reported its best quarterly profit in 13 years, earning $2.55 billion, or 0.61 cents a share. Excluding some one-time charges, the company earned 0.62 cents a share, easily topping analyst expectations of 0.50 cents a share. Revenues rose 18% to $33.1 billion from $28.1 billion last year.
U.S sales increased 16% showing resilience to rising U.S. gasoline prices. Canada, China, and India sales were all up by 8.6%, 18%, and 115% respectively. Expected shortages of new cars and trucks from Japanese auto makers throughout 2011 positions Ford to grab profitable market share. Ford raised its second quarter production forecast by 12,000 vehicles from 2Q2010, to about 1.5 million new cars and trucks.
Ford showed a pretax operating profit of $293 million in Europe, a vast improvement from the $51 million operating loss reported in the forth quarter, which was blamed for Ford's failure to meet analyst expectations last quarter.
Ford shares pushed as high as $16.18 earlier in the day, but closed up almost 1% at $15.66. The stock is down 4.8% since the beginning of the year
-Mike Biagi
Tuesday, April 26, 2011
Friday, April 22, 2011
MCD Announces Strong Sales and Earnings Growth for 1Q
McDonald’s Corporation (MCD) announced strong results yesterday for the first quarter ended March 31st, 2011, driven by international comparable sales growth. Global comparable sales were up 4.2%, with U.S. up 2.9%, Europe up 5.7% and Asia/Pacific, Middle East and Africa up 3.2%. Revenues increased 9% to $6.11 billion, just barely above analyst forecast. The Company reported earnings per share of $1.15, up 11% from the previous year.
In the U.S., 1Q comparable sales and customer traffic reflected menu changes such as the McCafe line, Oatmeal and featured products such as the 20-piece Chicken McNuggets and the Chipotle BBQ Bacon Angus Burger. MCD has maintained a long-term emphasis on everyday affordability, classic core menu favorites, signature food events and ongoing restaurant reimaging which contributed to performance across many markets.
The Company expects 2Q2011 results to be in line with or better than the first quarter’s, despite the current challenges of rising commodity costs in the U.S. and Europe. McDonald’s revised its expectations for full-year commodity inflation, now projected to be up 4-4.5% I the U.S. and in Europe, previously expected to be up 2.0%-2.5% in the U.S. and 3.5-4.5% in Europe. The stock closed at $76.91, down 1.90%.
~Sarah
In the U.S., 1Q comparable sales and customer traffic reflected menu changes such as the McCafe line, Oatmeal and featured products such as the 20-piece Chicken McNuggets and the Chipotle BBQ Bacon Angus Burger. MCD has maintained a long-term emphasis on everyday affordability, classic core menu favorites, signature food events and ongoing restaurant reimaging which contributed to performance across many markets.
The Company expects 2Q2011 results to be in line with or better than the first quarter’s, despite the current challenges of rising commodity costs in the U.S. and Europe. McDonald’s revised its expectations for full-year commodity inflation, now projected to be up 4-4.5% I the U.S. and in Europe, previously expected to be up 2.0%-2.5% in the U.S. and 3.5-4.5% in Europe. The stock closed at $76.91, down 1.90%.
~Sarah
Wednesday, April 20, 2011
WDC 3Q2011 Earnings Report
Western Digital reported results for the fiscal third quarter. The revenue fell by 15% to $2.25 billion with earning per share of 65 cents versus Street consensus of 66 cents. The week results were due to the shortages of computer processors and the disastrous earthquake and tsunami in Japan. Computer sales in the first quarter of 2011 fell for the first time since 2009 as tablet devices attracted buyers in droves and Japan focused on recovering from the earthquake and tsunami, according to research firm Gartner. For the quarter ended April 1, Western Digital reported a profit of $146 million, or 62 cents a share, down from $400 million, or $1.71 a share, a year earlier. Over the last five quarters, revenue has increased 15.5% on average year over year. The biggest increase came in the third quarter of the last fiscal year, when revenue rose 65.9% from the year earlier quarter.
Edwards Lifesciences Beats Estimates
Edwards Lifescience’s first-quarter earnings jumped 34%, driven by European growth in the transcatheter valve (TCV) market. Edwards saw its sales surge to $404.5 million, which surpassed the street’s estimate of $384 million. The company’s heart valve therapy segment, which includes TCV revenue, rose 25% to $244.9 million. The end result was reported earnings of $63.9 million, or $0.53 a share. Furthermore, management has raised its full-year earnings forecast, now expecting earnings between a range of $2.01 to $2.07 a share on $1.66 to $1.74 billion in revenue.
-Dave
Monday, April 18, 2011
Bank of America 1Q2011 Disappoints Again
On Friday, Bank of America (BAC) released another disappointing earnings report. Although BAC reported net income of $2.05B, that is a sizable decrease from the $3.18B a year ago. Earnings per share dropped to $0.17 from $0.28 a year ago. While comparing 1Q2011 with 1Q2010, it is important to note that the impressive trading revenues earned in 2010 will be difficult to repeat in today's economic climate; with that said, until BAC can successfully get a handle on its mortgage-related issues, it will continue to look less attractive than comparable large cap banks. Year-to-date, BAC is down 6.9% and has been the worst performer amongst its peers Citi (-6.54%), Wells Fargo (-4.74%), and JP Morgan (+3.62%).
On top of its lackluster earnings, BAC announced they would pay $1.1B to Assured Guaranty to resolve claims that they misrepresented $11B worth of mortgage-backed securities. After adding the cost of the loss-sharing reinsurance pact in the deal, the true cost is nearer to $1.6B. The securities in question were based off of mortgages issued by Countrywide - yet another setback in the seemingly endless Countrywide saga.
As negative as the environment surrounding Bank of America seems, I feel selling out at this point would be inappropriate. The $1.6B payout to Assured is a one-time hit and will go a long way in reducing the uncertainty surrounding mortgage-based liabilities. As mergers and acquisitions rapidly picks up there will be an excellent opportunity to replace some of the revenue which has disappeared from trading. Although short-term performance may be mediocre, on a longer-term basis I feel Bank of America continues to be worthy of remaining in the portfolio.
On top of its lackluster earnings, BAC announced they would pay $1.1B to Assured Guaranty to resolve claims that they misrepresented $11B worth of mortgage-backed securities. After adding the cost of the loss-sharing reinsurance pact in the deal, the true cost is nearer to $1.6B. The securities in question were based off of mortgages issued by Countrywide - yet another setback in the seemingly endless Countrywide saga.
As negative as the environment surrounding Bank of America seems, I feel selling out at this point would be inappropriate. The $1.6B payout to Assured is a one-time hit and will go a long way in reducing the uncertainty surrounding mortgage-based liabilities. As mergers and acquisitions rapidly picks up there will be an excellent opportunity to replace some of the revenue which has disappeared from trading. Although short-term performance may be mediocre, on a longer-term basis I feel Bank of America continues to be worthy of remaining in the portfolio.
Monday, April 11, 2011
Endo Pharmaceuticals Continues Buying Spree
Endo has reached an agreement to acquire American Medical Systems (AMS) for $30 per share, or $2.9 billion in cash, in another step to further diversity and strengthen Endo’s product portfolio. The acquisition strengthens Endo’s market position for medical devices and therapies used for male and female pelvic health, which aligns under Endo’s urology business which the company has been aggressive in building up. In addition, the acquisition also steers the company away from a reliance on branded pharmaceuticals, which are costly and time-consuming to develop. The company has committed financing from both Morgan Stanley and Bank of America which will help cover the cost of the acquisition, along with cash from Endo’s balance sheet. David Holveck has stated that this will end Endo’s buying spree, with the company now focused on realizing synergies, expected to reach $50mm in 2013, and on paying down its debt which has accumulated over the last several years. The deal is expected to close by the third quarter of this year and add an estimated $.60 to adjusted EPS next year, then contributing $.80 to EPS in 2013.
-Dave
Endo Pharmaceuticals Continues Buying Spree
Endo has reached an agreement to acquire American Medical Systems (AMS) for $30 per share, or $2.9 billion in cash, in another step to further diversity and strengthen Endo’s product portfolio. The acquisition strengthens Endo’s market position for medical devices and therapies used for male and female pelvic health, which aligns under Endo’s urology business which the company has been aggressive in building up. In addition, the acquisition also steers the company away from a reliance on branded pharmaceuticals, which are costly and time-consuming to develop. The company has committed financing from both Morgan Stanley and Bank of America which will help cover the cost of the acquisition, along with cash from Endo’s balance sheet. David Holveck has stated that this will end Endo’s buying spree, with the company now focused on realizing synergies, expected to reach $50mm in 2013, and on paying down its debt which has accumulated over the last several years. The deal is expected to close by the third quarter of this year and add an estimated $.60 to adjusted EPS next year, then contributing $.80 to EPS in 2013.
-Dave
-Dave
Subscribe to:
Posts (Atom)